Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth J O'Byrne

Showing results (1-10 of 163) with videos related to

Pageof 17
Sort By:
The Journal of Cell Biology|May 14, 2017
Nucleolar caspase-2: Protecting us from DNA damageKenneth J O'Byrne, Derek J Richard
Future Oncology (London, England)|June 9, 2016
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancerMarios P Decatris, Kenneth J O'Byrne
Cancer Treatment Reviews|September 24, 2013
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLCSusan Heavey, Kenneth J O'Byrne, Kathy Gately
Future Oncology (London, England)|May 9, 2019
Nivolumab plus ipilimumab in non-small-cell lung cancerMartin Reck, Hossein Borghaei, Kenneth J O'Byrne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung CancerMarios P Decatris, David Farrugia, Kenneth J O'Byrne
Cancer Metastasis Reviews|February 26, 2025
Epigenetic drugs in cancer therapyAmila Suraweera, Kenneth J O'Byrne, Derek J Richard
The Journal of the British Menopause Society|April 27, 2004
Management of endocrine resistant breast cancerSanthanam Sundar, Marios P Decatris, Kenneth J O'Byrne
Frontiers in Oncology|April 14, 2018
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACiAmila Suraweera, Kenneth J O'Byrne, Derek J Richard
Acta Oncologica (Stockholm, Sweden)|May 1, 2010
Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitorIan M Collins, Peter Beddy, Kenneth J O'Byrne
Oxford Medical Case Reports|July 28, 2025
RET-fusion metastatic colon cancer responding to selpercatinib-a case reportWilliam J Mullally, Michael Huo, Kenneth J O'Byrne
Pageof 17

Showing results (1-10 of 163) with videos related to

Sort By:
Pageof 17
The Journal of Cell Biology|May 14, 2017
Nucleolar caspase-2: Protecting us from DNA damageKenneth J O'Byrne, Derek J Richard
Future Oncology (London, England)|June 9, 2016
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancerMarios P Decatris, Kenneth J O'Byrne
Cancer Treatment Reviews|September 24, 2013
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLCSusan Heavey, Kenneth J O'Byrne, Kathy Gately
Future Oncology (London, England)|May 9, 2019
Nivolumab plus ipilimumab in non-small-cell lung cancerMartin Reck, Hossein Borghaei, Kenneth J O'Byrne
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung CancerMarios P Decatris, David Farrugia, Kenneth J O'Byrne
Cancer Metastasis Reviews|February 26, 2025
Epigenetic drugs in cancer therapyAmila Suraweera, Kenneth J O'Byrne, Derek J Richard
The Journal of the British Menopause Society|April 27, 2004
Management of endocrine resistant breast cancerSanthanam Sundar, Marios P Decatris, Kenneth J O'Byrne
Frontiers in Oncology|April 14, 2018
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACiAmila Suraweera, Kenneth J O'Byrne, Derek J Richard
Acta Oncologica (Stockholm, Sweden)|May 1, 2010
Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitorIan M Collins, Peter Beddy, Kenneth J O'Byrne
Oxford Medical Case Reports|July 28, 2025
RET-fusion metastatic colon cancer responding to selpercatinib-a case reportWilliam J Mullally, Michael Huo, Kenneth J O'Byrne
Pageof 17